Why did USFDA postpone its decision? Pfizer has been running clinical trials for its covid-19 vaccine for children for over three months.
The USFDA decided to hold off its decision saying it was specifically reviewing data on the three-shot vaccine instead of two shots.
This was because Pfizer-BioNTech found that their two-shot vaccine did not show efficacy in the age group of children it was studying—six months to four years.
The federal agency had taken up Pfizer’s application as the recent surge in covid-19 cases due to the Omicron outbreak had seen a notable increase in hospitalization among the youngest children. What does the evidence say? Experts are divided on the issue of vaccinating children.